Q32 Bio

Clinical-stage biotechnology company developing therapies targeting the complement and cytokine pathways to treat autoimmune, inflammatory, and other serious diseases.

Location
Cambridge, Massachusetts, USA
Founded
2018
Investors
1
Categories
biotech, autoimmune, immunology, complement-system

Investors

NameLocationTypeStagesPortfolio
AbingworthLondon, UK / Boston, USAbiotech-focused
seedseries-a+3
34